anti-angiogenic drugs

anti-angiogenic drugs

A group of currently experimental anticancer drugs that act by inhibiting the growth of the small blood vessels on which cancers depend for their growth. The group includes ANGIOSTATIN, ENDOSTATIN, THALIDOMIDE, SQUALAMINE, 2-methoxy-oestradiol (estradiol), vitaxin and marimastat.
References in periodicals archive ?
Objective: Many anti-angiogenic drugs are clinically used in several types of cancer to block angiogenesis, impair tumor growth, progression and dissemination.
Furthermore, alternative therapies such as anti-angiogenic drugs, laser therapy, Photodynamic Laser Therapy (PTD), and vitamins fails to completely cure Age Related Macular Degeneration and Retinitis Pigmentosa, thus giving momentum to the bionic eye market.
Anti-angiogenic drugs are used to try and prevent cancers from stimulating the growth of the blood vessels they need to survive and grow.
In the Research and Development area, the company completed key pilot studies on novel anti-angiogenic drugs and filed US and foreign patent applications for these agents.
Of particular interest is the identification of osteopontin (SPPI) as upregulated in poor outcome stroma, as we are in an era of large randomised clinical trials using potent bisphosphonate and anti-angiogenic drugs for breast cancer patients in the adjuvant setting.
Agricultural Center, Baton Rouge) notes that research on angiogenesis has attracted food scientists as well as molecular biologists, biomedical researchers, and others to this new field focusing on bioactive compounds that can serve as the basis for anti-angiogenic drugs or functional foods.
Enhanced Anti-Tumor Activity Achieved via Combination of Two Distinct Anti-Angiogenic Drugs presented at the AACR Annual Meeting 2012 --
This is a dramatic improvement upon anti-angiogenic drugs that primarily only stop the growth of new blood vessels.
The clinical and outstanding commercial success of Avastin, an antibody that blocks the activity of VEGF-A, clinically validated anti-angiogenic drugs as an effective means of inhibiting solid tumour growth.
Brooks was an assistant professor at the USC School of Medicine, during which time he also co-founded Cell Matrix Incorporated, a biotechnology company focused on anti-angiogenic drugs targeting cryptic ECM epitopes.